Akeso, Inc. (9926)

Quick facts

Phase 3 pipeline

• AK101 · Oncology
  AK101 is a bispecific antibody that simultaneously engages CD3 on T cells and PSMA on tumor cells to redirect immune attack against PSMA-expressing cancers.
• AK101 SC · Oncology
  AK101 is a bispecific antibody that simultaneously engages CD3 on T cells and PSMA on tumor cells to redirect T cell killing toward PSMA-expressing cancer cells.
• AK102 · Oncology
  AK102 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.
• AK104(IV) · Oncology
  AK104 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.
• AK104(SC) · Oncology
  AK104 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.
• AK111 · Oncology
  AK111 is a bispecific antibody that simultaneously engages CD3 on T cells and EGFR on tumor cells to redirect immune attack against EGFR-expressing cancers.
• AK112, Carboplatin, Paxlitaxel · Oncology
  AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and LAG-3 on T cells to enhance anti-tumor immunity, combined with carboplatin and paclitaxel chemotherapy for direct tumor cell killing.
• AK112, Gemcitabine, Cisplatin · Oncology
  AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, while gemcitabine and cisplatin are chemotherapy agents that damage tumor DNA.
• AK117 in combination with AK112 · Oncology
  AK117 and AK112 are bispecific antibodies that simultaneously engage immune checkpoint pathways to enhance anti-tumor T-cell responses.
• Durvalumab, Gemcitabine, Cisplatin · Oncology
  This combination uses durvalumab to block PD-L1 and enhance immune response while gemcitabine and cisplatin provide chemotherapy-induced tumor cell death.
• Ivonescimab, docetaxel · Oncology
  Ivonescimab is a PD-L1/CTLA-4 bispecific antibody that blocks two immune checkpoints simultaneously, while docetaxel is a microtubule-stabilizing chemotherapy agent, together enhancing anti-tumor immunity and direct cytotoxic effects.
• Oxaliplatin injection · Oncology
  Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication and induce apoptosis.
• Placebo+AK111 · Oncology
  AK111 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells toward cancer cells.
• Placebo, docetaxel · Oncology
  Docetaxel is a microtubule-stabilizing agent that prevents microtubule disassembly, leading to cell cycle arrest and apoptosis in cancer cells.
• Placebo in combination with Pembrolizumab · Oncology
  Placebo serves as a control comparator in a combination study with Pembrolizumab, a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses.
• Tislelizumab, Carboplatin, Paxlitaxel · Oncology
  Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response. By binding to PD-1, tislelizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and other cells in the tumor microenvironment. This blockade enhances the immune response against cancer cells.

Phase 2 pipeline

• AK104 lenvatinib · Oncology
  AK104 lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR).
• AK112 high dose · Oncology
  AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.
• AK112 low dose
• AK117 · Oncology
  AK117 is a small molecule targeting the CD47/SIRPα axis.
• AK130
• AK131 · Oncology
  AK131 is a small molecule targeting the CD47/SIRPα axis to modulate the immune system.
• AK139

Phase 1 pipeline

• AK101 IV
• AK104 IV infusion；Chiauranib oral · Oncology
  Tyrosine kinase inhibitor
• AK104 plus Carboplatin and paclitaxel
• AK104 plus Carboplatin and Pemetrexed
• AK109
• AK112, Cadonilimab, nab-paclitaxel, gemcitabine · Oncology
  CD47 antibody
• AK112, nab-paclitaxel, gemcitabine · Oncology
  Inhibits microtubule dynamics by binding to tubulin, thereby inhibiting cell division
• AK114
• AK115
• AK119
• AK127
• AK127 in combination with AK112
• AK129
• AK129 IV infusion
• AK132
• AK135
• AK137
• AK138D1
• AK146D1 for injection
• AK152
• AK154
• Ebronucimab · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Akeso, Inc. portfolio CI brief
• Akeso, Inc. pipeline updates RSS